0001593968-22-001495.txt : 20221005
0001593968-22-001495.hdr.sgml : 20221005
20221005160255
ACCESSION NUMBER: 0001593968-22-001495
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20221003
FILED AS OF DATE: 20221005
DATE AS OF CHANGE: 20221005
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Amado Rafael
CENTRAL INDEX KEY: 0001662119
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38693
FILM NUMBER: 221295597
MAIL ADDRESS:
STREET 1: 210 EAST GRAND AVE
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Allogene Therapeutics, Inc.
CENTRAL INDEX KEY: 0001737287
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 823562771
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 210 EAST GRAND AVENUE
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
BUSINESS PHONE: (650) 457-2700
MAIL ADDRESS:
STREET 1: 210 EAST GRAND AVENUE
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
4
1
primary_01.xml
PRIMARY DOCUMENT
X0306
4
2022-10-03
0001737287
Allogene Therapeutics, Inc.
ALLO
0001662119
Amado Rafael
210 EAST GRAND AVENUE
SOUTH SAN FRANCISCO
CA
94080
true
EVP of R&D
Common Stock
2022-10-03
2022-10-03
4
F
false
8968
11.0617
D
531290
D
Represents the number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.01 to $11.08, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
Includes 1 share of the Issuer's common stock acquired by the reporting person on September 15, 2022 pursuant to an employee stock purchase program
/s/Veer Bhavnagri, Attorney-in-Fact
2022-10-05